Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 26CNS 13Lymphoid 11Breast 11Gastrointestinal 9Myeloid 8Thoracic 7Sarcoma 7Genitourinary 7Plasma cell 5Head & Neck 5Classical hematology 5Other solid neoplasm 4Dermatologic 3Endocrine 2Tumor-Agnostic 1Other neoplasm 1Gynecologic 1

Conditions

Advanced Malignant Neoplasm 1

Interventions

Cyclophosphamide 13Biopsy 13fludarabine phosphate 9Whole-Body Irradiation 9Surveys and Questionnaires 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Polymerase Chain Reaction 7Mycophenolic Acid 7Early Intervention, Educational 7Tacrolimus 6Gene Expression Profiling 6Educational Status 6Colposcopy 6Carboplatin 6fludarabine 5Paclitaxel 5Microarray Analysis 5Methotrexate 5Methods 5Melphalan 5Immunohistochemistry 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tipifarnib × Other neoplasm × Clear all
NCT00244972 2017-04-27

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
74 enrolled
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡